GTHX G1 Therapeutics
- 4.680
- -0.010-0.21%
- 4.720
- +0.040+0.85%
G1 Therapeutics News
Daily rights tracking | WSB concept stocks are once again in a rush of emptying! AMC and GME options transactions surged, and a single call earned more than 55 times the option premium
Alibaba rose nearly 6% overnight and will release pre-market results for today's US stocks. Overnight options transactions increased about 2 times month-on-month to 560,000, and the stock continued to have a high bullish ratio, rising from 69.9% to 73.5%. This Friday, the call with an exercise price of 85 US dollars topped the list with nearly 25,000 transactions, with nearly 24,000 unclosed positions.
Daily rights tracking | Amazon's bullish ratio rose to 70%, and some large players spent 300 million US dollars to buy calls; Roblox's performance plummeted by more than 22% after that, making 9 times profit from a single PUT
Energy Transfer traded 2.45 million overnight options, up 15 times from the average daily volume, and the bullish ratio soared from 67% to 99%. The transaction volume was based on the top order and found that some large investors bought a forward call option when the stock price was 16.24 US dollars, and the turnover exceeded 30 million US dollars.
What's Going On With G1 Therapeutics Stock?
G1 Therapeutics, Inc. (NASDAQ:GTHX) shares are trading higher Thursday amid M&A blog speculation of a takeover offer. What To Know:According to a report from Seeking Alpha, G1 Therapeutics has receive
G1 Therapeutics Jumps Amid Takeover Speculation
Watching G1 Therapeutics; Traders Circulate M&A Blog Suggesting Company Rumored To Have A CVR Aspect That Could Value The Company At Between $12-$14/Share
Watching G1 Therapeutics; Traders Circulate M&A Blog Suggesting Company Rumored To Have A CVR Aspect That Could Value The Company At Between $12-$14/Share
G1 Therapeutics, Inc. (NASDAQ:GTHX) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
HC Wainwright & Co. : The G1 Therapeutics (GTHX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $9.00.
HC Wainwright & Co. : The G1 Therapeutics (GTHX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $9.00.
HC Wainwright & Co. Reiterates Buy on G1 Therapeutics, Maintains $9 Price Target
HC Wainwright & Co. analyst Edward White reiterates G1 Therapeutics with a Buy and maintains $9 price target.
Optimistic Buy Rating for G1 Therapeutics Amidst Solid Financial Footing and Cosela's Market Expansion
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., May 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 2,100
Evaluating G1 Therapeutics: Insights From 5 Financial Analysts
Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on G1 Therapeutics (NASDAQ:GTHX) in the last three months.The following table summarizes their rece
Earnings Call Summary | G1 Therapeutics(GTHX.US) Q1 2024 Earnings Conference
The following is a summary of the G1 Therapeutics, Inc. (GTHX) Q1 2024 Earnings Call Transcript:Financial Performance:G1 Therapeutics reported a 34% increase in COSELA's net sales, amounting to $14.1
G1 Therapeutics: A Buy Rating on Promising Trials and Robust Financial Outlook
G1 Therapeutics Inc (GTHX) Q1 2024 Earnings: Close Alignment With Analyst Revenue Projections
Earnings Flash (GTHX) G1 THERAPEUTICS Reports Q1 Revenue $14.5M, Vs. Street Est of $15.1M
06:40 AM EDT, 05/01/2024 (MT Newswires) -- Earnings Flash (GTHX) G1 THERAPEUTICS Reports Q1 Revenue $14.5M, vs. Street Est of $15.1M
G1 Therapeutics Reports Mixed Q1 Results; Reaffirms FY24 Outlook
G1 Therapeutics Backs FY24 Net COSELA Rev Guidance of $60M to $70 M >GTHX
G1 Therapeutics Backs FY24 Net COSELA Rev Guidance of $60M to $70 M >GTHX
G1 Therapeutics Q1 2024 GAAP EPS $(0.20), Inline, Sales $14.476M Miss $15.259M Estimate
G1 Therapeutics (NASDAQ:GTHX) reported quarterly losses of $(0.20) per share which met the analyst consensus estimate. This is a 62.26 percent increase over losses of $(0.53) per share from the same p
G1 Therapeutics 1Q Loss/Shr 20c >GTHX
G1 Therapeutics 1Q Loss/Shr 20c >GTHX
Press Release: G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights
G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights - Achieved $14.1 Million in Net Revenue from Sales of COSELA(R) (trilaciclib) for First Quarter 2024 - - Reaf
Analysis
Price Target
No Data
